



899 NORTH CAPITOL ST. NE – 2ND FLR. WASHINGTON, DC 20002

June 3, 2021

9:30 am

OPEN SESSION AGENDA (VIA ZOOM MEETING DUE TO THE COVID-19 PUBLIC HEALTH EMERGENCY)

Board of Pharmacy Mission Statement:

"To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians."

CAL	ΙT	0	OR	DF	·R·
\sim	1	•	$\boldsymbol{\smile}$	-	- I N -

PRESIDING:

BOARD MEMBERSHIP/ATTENDANCE:

BOARD MEMBERS:		
	DR. TAMARA MCCANTS, PHARM.D. R.PH CHAIRPERSON	
	Mr. Alan Friedman, R.PH, Vice Chairperson	
	Dr. Benjamin MILES, PHARM.D. R.PH	
	Dr. Ashlee Bow, Pharm.D. R.PH	
	Dr. Allison Hill, Pharm.D. R.PH	
	Gregory Cendana, Consumer Member	
STAFF:	Shauna White, Executive Director	
	Karin Barron, Health Licensing Specialist	
	LUANNE GREENAWAY, PROGRAM SPECIALIST	
	COUNTEE GILLIAM, BOARD INVESTIGATOR	
LEGAL STAFF:	CARLA WILLIAMS, SENIOR ASSISTANT GENERAL COUNSEL	
\ //CITODS		
VISITORS:		

Open Session Agenda

Quorum:

Introduction:		
o6o3-O-o1	Approval of the Open Session Meeting Minutes for April 1, 2021 Approval of the Open Session Meeting Minutes for	
	May 6, 2021	
Consent Agenda	None	
<u>Chairperson</u> <u>Report</u>	NABP Annual Meeting- May 13-14, 2021	Dr. Tamara McCants
Executive Director Report	 Statistical Report on Pharmacy professionals in the District of Columbia Prescription Drug Monitoring Program Updates Pharmacist and Pharmacy Technician Renewals DCRx (DC Center for Rational Prescribing) Licensure Audit Opioid Labeling Legislation Pharmacy Security Updates New Online Licensing System 	Dr. Shauna White
Senior Assistant General Counsel Report		
	None	
Subcommittee Reports		
0601-O-02	Legislative and Regulatory Subcommittee Report	Mr. Friedman
0601-0-03	Communications Subcommittee Report	Dr. Ashlee Bow
NABP E- Newsletter	May 19, 2021	Dr. Tamara McCants

	NABP Membership Approves Six Resolutions at the Association's 117th Annual Meeting	
	2021-2022 Executive Committee Inaugurated at NABP's 117th Annual Meeting	
	NABP Announces 2021 Leaders at the Forefront of Public Health Protection	
	FDA Warns of Biological Products Being Offered to Patients Outside the Scope of an Approved BLA	
	New USP Guide Provides Strategies, Techniques for Maximizing Moderna's COVID-19 Vaccine Doses	
	New Study Shows Extended-Release Buprenorphine is Preferred by Patients in Treating OUD	
	FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for EUA in Adolescents	
	June 26, 2021	
	Reminder: Share Feedback on ACPE Standards Revision Process	
	Counterfeit Pill Production Remains a Nationwide Threat, Updated Report Urges Action	
	New CDC Study Shows COVID-19 Vaccines Are 94% Effective at Preventing Illness Among Health Care Workers	
	Study Results Show Pfizer's COVID-19 Vaccine Provides Strong Protection Against Variants	
	Warning Letter Issued for Unapproved and Misbranded COVID-19 Products	
	Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/ .	
Comments from the Public		
Motion to Adjourn the Open Session	"Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports	

concerning ongoing or planned investigations pursuant to § 2-	
575(b)(14)."(Roll Call Vote)	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code $\S 2-575(b)$ for the reasons set forth in the motion.

Open Session Meeting Adjourned at _:_ AM.

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.